The EU funded p-medicine project is online. The new website (p-medicine.eu) refers to interviews with the project experts about their work: developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient.
Within the scope of the 2nd Summer School in Computational Oncology, which took place from June 24-28, 2013 at Schloss Dagstuhl, Wadern Germany, several p-medicine experts were interviewed about the project and their work.
The interviews feature:
- Prof. Dr. Norbert Graf, Saarland University, Germany, and coordinator of p-medicine, on how the project started, the pitfalls they faced and the benefits the tools will bring towards clinicians and patients;
- David Perez-Rey, Universidad Politecnica de Madrid, Spain, on his involvement with semantic interoperability and data model issues in p-medicine;
- Prof. Yuzuru Tanaka, Hokkaido University, Japan, on his role in p-medicine helping create the Trial Outline Builder (TOB) for visualizing clinical trials;
- Dr. Anca Bucur, Philips Electronics, the Netherlands, on Philips’ involvement in p-medicine in helping create the Clinical Decision Support tool to help clinicians choose the best treatment for patients;
- Prof. Rod Hose of Sheffield University, U.K., on the VPH-Share tool and its collaboration with p-medicine;
- Dr. Dieter Wallach, managing director of Ergosign, Germany, on creating user interfaces for clinicians and patients. He also talks about the constraints that they have faced and the differences that a clinician or patient will see when using a tool.
Watch the videos here.
'p-medicine - From data sharing and integration via VPH models to personalized medicine' is a 4-year Integrated Project co-funded under the European Community’s 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient.
In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to create support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized therapy.